Abstract:
:Dasatinib was approved for the treatment of chronic phase (CP) chronic myeloid leukemia (CML) patients in first line therapy based on the demonstration of efficacy and safety reported in patients enrolled in clinical trials. We describe a multicentric Italian "real-life" experience of dasatinib used as frontline treatment outside clinical trials. One hundred and nine patients (median age 54 years) were treated from January 2012 to December 2013. Increased incidence of high risk patients were detected according to stratification (26% according to Sokal score, 19% according to Euro score and 16% according to EUTOS) when compared to company sponsored studies. Median time from diagnosis to start of dasatinib was 18 days. Ten patients received unscheduled starting dose (6 patients 50mg and 4 patients 80 mg QD), whereas 99 patients started with 100mg QD. At 3 months, 92% of patients achieved a BCR-ABL ratio less than 10%. At 6 months, the rate of CCyR was 91% and the rate of MR3 was 40%, with 8% of the patients reaching MR4.5. Ninety-three patients were evaluable at 12 months: the rate of MR3 was 62%, with MR4.5 being achieved by 19% of the patients. At a median follow-up of 12 months, 27 patients (24.7%) were receiving the drug at reduced dose. Two patients (1.8%) experienced a lymphoid blast crisis and the overall incidence of resistance was 8%. As regards safety, the major side effects recorded were thrombocytopenia, neutropenia and pleural effusions, which occurred in 22%, 10% and 8% of patients, respectively. Present results, achieved in a large cohort of patients treated outside clinical trials, further confirm the efficacy and safety of dasatinib as firstline treatment in CML.
journal_name
Leuk Resjournal_title
Leukemia researchauthors
Breccia M,Stagno F,Luciano L,Abruzzese E,Annunziata M,D'Adda M,Maggi A,Sgherza N,Russo-Rossi A,Pregno P,Castagnetti F,Iurlo A,Latagliata R,Cedrone M,Di Renzo N,Sorà F,Rege-Cambrin G,La Nasa G,Scortechini AR,Greco Gdoi
10.1016/j.leukres.2015.11.008subject
Has Abstractpub_date
2016-01-01 00:00:00pages
24-9eissn
0145-2126issn
1873-5835pii
S0145-2126(15)30547-6journal_volume
40pub_type
杂志文章,多中心研究abstract::The glycosylation of beta-hexosaminidase was investigated in the transformed cell-line, CCRF/CEM, derived from a human acute lymphoblastic leukaemia, and comparisons were made with enzyme from normal human skin fibroblasts. A series of studies including neuraminidase sensitivity, lectin chromatography, Biogel P4 chrom...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(88)90146-4
更新日期:1988-01-01 00:00:00
abstract::Occupational and industrial exposures have been implicated in the etiology of leukemia, yet uncertainty remains regarding potential high risk occupations. We examined the associations between self-reported occupations and hobbies and acute leukemia risk using data from 811 cases and 637 controls participating in a cas...
journal_title:Leukemia research
pub_type: 杂志文章,多中心研究
doi:10.1016/j.leukres.2005.03.002
更新日期:2005-10-01 00:00:00
abstract::A role for post-induction chemotherapy for adult patients with acute myeloblastic leukemia in remission has not been established. We have studied 125 patients with acute myeloblastic leukemia in complete remission to determine the effect on survival of remission maintenance therapy and of early reinduction therapy giv...
journal_title:Leukemia research
pub_type: 临床试验,杂志文章,随机对照试验
doi:10.1016/0145-2126(88)90136-1
更新日期:1988-01-01 00:00:00
abstract::Clofarabine (CLO), a purine nucleoside analog with promising efficacy in acute myeloid leukemia (AML), inhibits the ribonucleotidereductase, p53R2. We have shown that p53R2 mRNA is up-regulated by decitabine (DEC), another drug with promising activity in AML. We developed a pharmacodynamic model to characterize the in...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2012.07.015
更新日期:2012-11-01 00:00:00
abstract::Aggressive systemic mastocytosis (ASM) is a hematopoietic neoplasm characterized by infiltration of visceral organs by neoplastic mast cells (MCs) with consecutive organopathy and respective clinical and laboratory findings (so called C-Findings). Whereas, it is generally appreciated that patients with ASM are candida...
journal_title:Leukemia research
pub_type: 杂志文章,评审
doi:10.1016/s0145-2126(03)00259-5
更新日期:2004-03-01 00:00:00
abstract::Hyperdiploid and non-hyperdiploid multiple myeloma represents distinct biological entities characterized by different patterns of genetic changes. We sought to determine whether ploidy category (non-hyperdiploid versus hyperdiploid) remains stable over time from diagnosis to progression. Of the 43 patients studied (39...
journal_title:Leukemia research
pub_type: 临床试验,杂志文章
doi:10.1016/j.leukres.2005.07.004
更新日期:2006-03-01 00:00:00
abstract::The prognostic relevance of 12p deletion is controversial in multiple myeloma (MM) and the status of 12p deletion is unknown in other plasma cell disorders. We investigated 12p deletion in 88 patients with MM, 19 patients with monoclonal gammopathy of undetermined significance (MGUS), and 17 patients with plasma cell ...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2011.07.030
更新日期:2012-01-01 00:00:00
abstract::To elucidate the biological characteristics of chronic myelogenous leukemia (CML) cells, we observed morphological and functional changes of CML cells during primary long-term culture, in which their morphology changed to that of myofibroblasts with similar molecular characteristics to the parental CML cells including...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2010.09.019
更新日期:2011-05-01 00:00:00
abstract::Reversal of drug resistance is of pivotal importance in order to improve the results of chemotherapy. Monitoring of such reversal is necessary in order to analyze the results of clinical trials. Nonetheless, the leukemia cell population to eradicate is the leukemia initiating cells characterized by a CD34+CD38- phenot...
journal_title:Leukemia research
pub_type: 评论,社论
doi:10.1016/j.leukres.2008.09.022
更新日期:2009-06-01 00:00:00
abstract::Leukemic cell lines have become important tools for studies of disease providing a monoclonal cell population that can be extensively expanded in vitro while preserving leukemic cellular characteristics. However, studies of chronic lymphocytic leukemia (CLL) have been impeded in part by the lack of continuous human ce...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2015.10.008
更新日期:2016-01-01 00:00:00
abstract::The revised IPSS (IPSS-R) was developed aiming at a better prognostication, taking into account patients treated with best supportive care. We herein validated this model on the basis of data from 1314 patients who received BSC only as well as patients who underwent induction chemotherapy (n=214) or allogeneic transpl...
journal_title:Leukemia research
pub_type: 杂志文章,多中心研究
doi:10.1016/j.leukres.2013.10.013
更新日期:2014-01-01 00:00:00
abstract::Using a short term liquid system we have shown that blood from some patients with primary myelofibrosis (PMF) and chronic granulocytic leukaemia (CGL) in megakaryoblastic transformation (CGL-Mk) gives rise to large numbers of progenitor cells committed to the megakaryocyte (Mk) lineage. As assessed by indirect immunof...
journal_title:Leukemia research
pub_type: 历史文章,杂志文章
doi:10.1016/0145-2126(85)90108-0
更新日期:1985-01-01 00:00:00
abstract::Limited information is available on the relationship between expression of some additional aberrant phenotypic features and outcome of acute promyelocytic leukemia (APL) patients. Here, we set out to assess the frequency of CD15 and CD56 expression, and their prognostic value in a large series of APL patients. One hun...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2013.11.008
更新日期:2014-02-01 00:00:00
abstract::To examine the relationship between viability of acute myelogenous leukemia (AML) blasts in liquid suspension culture and the occurrence of myeloid maturation in culture, total and differential cell counts and viability as determined by trypan blue dye exclusion were followed over 21 days of culture. A significant pos...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(88)90098-7
更新日期:1988-01-01 00:00:00
abstract::Bcr-Abl tyrosine kinase inhibitor induces apoptosis and erythroid differentiation of K562 cells. During this erythroid differentiation, c-Myc and cyclin D1 transcripts are transiently downregulated. Accordingly, we studied the effect of cyclin D1 overexpression on erythroid differentiation. After treatment with 250 nM...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2003.10.022
更新日期:2004-06-01 00:00:00
abstract:BACKGROUND:Chromosomal aberrations at the ETV6 gene locus on 12p13.2 are common in bone marrow samples involved by blastic plasmacytoid dendritic cell neoplasm (BPDCN). However, their pathogenic role, incidence in cutaneous BPDCN lesions, and clinical significance have not been assessed systematically. RESULTS:The stu...
journal_title:Leukemia research
pub_type: 临床试验,杂志文章
doi:10.1016/j.leukres.2018.09.006
更新日期:2018-10-01 00:00:00
abstract::Chemotherapy resistance has been considered as a major problem for multiple myeloma (MM) treatment and bone marrow microenvironment plays a crucial role in the MM progression and chemoresistance. Recent studies reported that bone marrow mesenchymal stem cells derived from MM patients (MM-MSCs) revealed various charact...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2017.07.002
更新日期:2017-09-01 00:00:00
abstract::We determined the position of the breakpoint within the bcr gene in 22 patients with Philadelphia-positive chronic myelocytic leukemia using conventional Southern-blots and analyzed its relationship to thrombopoiesis. After DNA digestion with restriction endonucleases (Hind III, Bam HI and Bgl II), we localized the br...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(91)90113-8
更新日期:1991-01-01 00:00:00
abstract::Imatinib is a highly effective drug for the treatment of chronic myeloid leukemia (CML) that targets the BCR-ABL kinase. However, a number of patients have CML that is resistant to Imatinib treatment. In this report, we developed AGM130 as a potential therapeutic drug for Imatinib-resistant CML treatment. The AGM130 c...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2012.12.017
更新日期:2013-04-01 00:00:00
abstract:BACKGROUND:Myeloid sarcoma is a tumor mass that consists of myeloblasts or immature myeloid cells at an extramedullary site. Pathological diagnosis is very difficult based on morphology if systemic signs of disease are absent. The subtype of myeloid sarcoma is also minimally identifiable in the histological picture. F...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2016.01.002
更新日期:2016-03-01 00:00:00
abstract::Like CD19 or CD56, CD22 in non-lymphoid leukemia has been considered an aberrantly expressed antigen. CD22 had been believed to be restricted to B lymphoid, however, it was also found to be expressed in human basophils. Mature basophils are unique granulocytes expressing CD13, CD22 and CD25. To estimate whether the ex...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2003.10.034
更新日期:2004-07-01 00:00:00
abstract::IL-3 stimulated the production of IL-6 from a bone marrow-adherent cell population, macrophages and from hemopoietic supportive stromal cell lines. It also induced IL-6 production from a stem cell-enriched population of bone marrow cells which did not produce IL-6 without stimulation. In contrast, stimulation with IL-...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(91)90180-2
更新日期:1991-01-01 00:00:00
abstract::Forty patients with high risk myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML) preceded by MDS were treated with intensive induction and consolidation chemotherapy in a prospective multicenter pilot study. They were given two cycles of cytarabine 100 mg/m with 12-h intervals on days 1-7 and idarubicin 12...
journal_title:Leukemia research
pub_type: 临床试验,杂志文章,多中心研究
doi:10.1016/s0145-2126(96)00116-6
更新日期:1997-02-01 00:00:00
abstract::We investigated the accumulation of DNA strand breaks in a human promyelocytic leukemia cell line, HL-60, treated with methotrexate (MTX) and 1-beta-D-arabinofuranosylcytosine (Ara-C). The sequential treatment with MTX then Ara-C had a synergistic effect on the formation of DNA strand breaks, which was dependent on MT...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(89)90139-2
更新日期:1989-01-01 00:00:00
abstract::Adenosine deaminase (ADA) and purine nucleoside phosphorylase (PNP) were measured in normal human and in malignant lymphoid cells. Thymocytes had high ADA activity (21.2 +/- 6.8 10(3) nM/h/mg) and low PNP activity (1.2 +/- 0.6), whereas T peripheral blood lymphocytes (PBL) had low ADA activity (1.20 +/- 0.22) and high...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(82)90027-3
更新日期:1982-01-01 00:00:00
abstract::We investigated the transcript levels of genes STAT1, STAT3, STAT5A and STAT5B in the diagnostic samples of childhood ALL patients and compared them to those of healthy controls in order to characterize STAT gene expression in childhood ALL. As compared to controls, ALL patients exhibit markedly decreased transcript l...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2015.09.004
更新日期:2015-09-11 00:00:00
abstract::The study was undertaken to elucidate the regulatory roles of GMP reductase (GMPR) and IMP dehydrogenase (IMPDH) on purine interconversion during differentiation. Treatment of HL-60 cells with retinoic acid (1 microM) induced granulocytic differentiation which was accompanied with a 2.4-fold increase in GMPR and 55% d...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(92)90002-o
更新日期:1992-06-01 00:00:00
abstract:BACKGROUND:The skin is the common extranasal sites in extranodal natural killer (NK) / T - cell lymphoma, (ENKTL). However, data regarding cutaneous ENKTL are relatively scarce. Thus, we performed a large retrospective study to analyze clinical features and treatment outcomes of cutaneous ENKTL. PATIENTS AND METHODS:S...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2019.106284
更新日期:2020-01-01 00:00:00
abstract::We analysed the optimal conditions for autologous bone marrow purging using complement binding monoclonal antibodies (mAbs). Twelve mAbs belonging to four clusters (CD9, CD10, CD19, CD24), alone or combined were evaluated by using direct cytotoxicity and clonogenic assays. We observed the following data: (1) optimal c...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/0145-2126(87)90117-2
更新日期:1987-01-01 00:00:00
abstract::Many evidences have shown that dietary intake of cruciferous vegetables could protect against the risk of various types of malignancies. Benzyl isothiocyanate (BITC), one of the compounds from cruciferous vegetables, had shown induced cell cycle arrest and apoptosis in cancer cells. However, there is no available info...
journal_title:Leukemia research
pub_type: 杂志文章
doi:10.1016/j.leukres.2009.01.030
更新日期:2009-11-01 00:00:00